drugset / Trial / NCT00846430

Medical Treatment of "High-Risk" Neurofibromas

NCT00846430

Phase 2 Completed 9 enrolled Corewell Health West
NaSingle-groupOpen-labelTreatment

Summary

Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.

Timeline

Start
2008-10
Primary completion
2017-04
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified
Subject Peginterferon alfa-2b Protein / enzyme biologic
Subject Temozolomide Small molecule
Subject Vincristine Small molecule